![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody-drug conjugate. It is being evaluated for the treatment of HER2-positive early-stage breast cancer With residual invasive disease after neoadjuvant treatment.
Lead Product(s): Kadcyla
Therapeutic Area: Oncology Product Name: Kadcyla
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Kadcyla
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023